ColActive Plus
Covalon Technologies, Ltd. · Decision date Sep 9, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for ColActive Plus, a collagen matrix dressing from Covalon Technologies, Ltd., under 510(k) K260652. The agency page lists a decision date of 09/09/2026 and a receipt date of 02/27/2026, while the clearance letter itself is dated September 9, 2026 and cites a submission dated August 7, 2026 and received August 10, 2026; the source does not reconcile these dates. SESE is a clearance finding, not premarket approval.
The subject device is a sterile, single-use absorbent dressing of fish-skin collagen gelatin with sodium alginate, CMC and EDTA, cleared for adult full- and partial-thickness wounds. Its listed predicate is ColActive Collagen Wound Dressing (K050177), product code KGN. The summary describes differences in collagen animal source, added materials, sterilization method, a larger 7 x 7 inch size and a 7-day maximum duration of use versus no stated limit for the predicate. The summary states that bench, animal and clinical testing were used to assess these differences, but the supplied excerpts do not report results, and the review panel is listed as General & Plastic Surgery while the specialty field is Unknown.
The source does not state whether the device is prescription or over-the-counter, and the indications text is limited to the enclosure as provided.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Sep 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260652
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Covalon Technologies, Ltd.
- Product code
- KGN
- Decision code
- SESE
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wound Dressing With Animal-Derived Material(S).
- Applicant
- Covalon Technologies, Ltd.
- Product code
- KGN
- FDA device class
- U
FDA decision timeline
K260652 received
Application receipt date recorded by FDA.
K260652 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KGN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Kerecis Express (50250)K260058 | Kerecis Limited | 510(k) clearance | Oct 30, 2026 | FDA |
| Berkeley Advanced Biomaterials | 510(k) clearance | Oct 22, 2026 | FDA | |
epi-ConneKt Wound MatrixK260530 | MLM Biologics, Inc. | 510(k) clearance | Oct 15, 2026 | FDA |
| Berkeley Advanced Biomaterials | 510(k) clearance | Aug 27, 2026 | FDA | |
Collagen Wound PowderK260596 | Ventris Medical | 510(k) clearance | Jul 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Covalon Technologies, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mississauga
Sources and methodology
- Original FDA record: K260652
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


